

# Thoracic Disease-Oriented Team

---

Clinical Research Treatment Flowchart

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

ALK

1L

2L

**UCI 21-241 (Nuvalent)**  
NVL-655 + ALK inhibitor

Mechanism: TKI Inhibitor  
Coord: Keagan Buttigieg  
Accrual: 6/10

ADVANCED/METASTATIC

Exon 18

1L

2L

**UCI 23-95 (HARMONI)**  
 Randomized Double Blind:  
 AK112/Placebo + Pem + Carbo

Mechanism: Novel PD-1/VEGF  
 bispecific antibody w/ Chemo  
 Coord: Celest Ramirez  
 Accrual: 0/10

Open to Accrual

Low Accruing

Pending Activation

Exon 19 del or L858R

**UCI 20-119 (Janssen)**  
 JNJ-6118637 + Lazertinib

Mechanism: TKI  
 Coord: Richard Chang  
 Accrual: 10/13

**UCI 22-121 (Jintsbio)**  
 JIN-A02 Monotherapy

Mechanism: TKI  
 Coord: Richard Chang  
 Accrual: 0/7

**UCI 22-217(Janssen)**  
 Amivantamb + Lazertinib w/ or  
 without Carbo + Pemetrexed

Mechanism: Antibody drug w/  
 TKI and Chemo  
 Coord: Celest Ramirez  
 Accrual: 2/5

Exon 20

Exon 21

1L

**UCI 22-217(Janssen)**  
 Amivantamb + Lazertinib w/ or without Carbo + Pemetrexed

Mechanism: Antibody drug w/ TKI and Chemo  
 Coord: Celest Ramirez  
 Accrual: 2/5

2L

**UCI 23-95 (HARMONI)**  
 Randomized Double Blind: AK112/Placebo + Pem + Carbo

Mechanism: Novel PD-1/VEGF bispecific antibody w/ Chemo  
 Coord: Celest Ramirez  
 Accrual: 1/5

UCI 22-59 (ADAURA)

Randomized: Osimertinib or Placebo

Mechanism: TKI  
Coord: Jenny Choe  
Accrual: 0/10

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

cMET and EGFR

1L

2L

UCI 20-195 (MCLA-129)

Mechanism: Antibody Drug  
Coord: Cynthia Gonzalez  
Accrual: 12/20

## ADVANCED/METASTATIC

1L

**UCI 23-66 (Boehringer Ingelheim)**

BI-1810631 Monotherapy

Mechanism: TKI  
 Cord: Keagan Buttigieg  
 Accrual: 0/5

2L

Exon 19

Exon 20

**UCI 21-234 (AstraZeneca)**

Randomized: Arm 1: T-DXD(Trastuzumab Deruxtecan) or Arm 2:  
 Cisplatin or Carbo + Pemetrexed + Pembrolizumab

\*Treatment Naïve for palliative intent systemic therapy in locally advanced or metastatic disease.


\*Documented Her2 Exon 19 or 20 mutation

\*Tumor sample must be available for central testing from fresh or archival.

\*No Slot Required prior to consenting if mutation of HER2 is available.

Accrual: 1/10

ADVANCED/METASTATIC

 Open to Accrual

 Low Accruing

 Pending Activation

KRAS G12C

G12A, G12D, G12R, G12S,  
G12V

1L

**UCI 22-30 (D3S-001-100):**D3 Bio

Mechanism: TKI  
 Coord: Richard Chang  
 Accrual: 0/3

2L

**UCI 22-88 (RMC-6291  
Revolution Med)**

Mechanism: TKI  
 Coord: Richard Chang  
 Accrual: 3/25

**UCI 21-53 (Loxo Oncology,  
Inc. LOXO-RAS-20001)**

Mechanism: TKI  
 Coord: Jenny Choe  
 Accrual: 6/8

**UCI 18-78 (Mirati MRTX-  
849)**


Mechanism: TKI  
 Coord: Celest Ramirez  
 24/40

**UCI 22-87 (RMC-6236  
Revolution Med)**

Mechanism: TKI  
 Coordinator: Oliver Quines  
 Accrual: 6/20



## ADVANCED/METASTATIC

 Open to Accrual Low Accruing Pending Activation**NRG-LU007**

Treatment: (Randomized) Group 1:  
Atezolizumab Alone. Group 2:  
Atezolizumab + Radiation

Mechanism: Immunotherapy + Radiation  
Coord: Richard Chang  
Accrual: 1/5

**UCI 23-178**

Treatment: BL-B01D1 IV  
Mechanism: IP binding to EGFR/HER3,  
antibody fragments of IP bind to  
EGFR/HER3, Fc segment of (ADCC)  
Coord: TBA  
Accrual: 0/10

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

NTRK 1-3

1L

2L

UCI 16-79 (TPX-0005)

Mechanism: TKI  
Coord: Stephanie Fernandez  
Accrual: 16/27

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

All Comers

3L

---

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

ROR2

1L

2L

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation


ROS1

1L

2L

UCI 21-47 ( NVL-520 Nuvalent)  
Mechanism: TKI  
Coord: Keagan Buttigieg  
Accrual: 6/10

## Database & Repository

 Open to Accrual

 Low Accruing

 Pending Activation

**UCI 21-238:** Database & Repository of  
Asian female never smokers w/ low  
dose CT scan Screening Study

Mechanism: D  
Coord: TBD  
Accrual: 0/100

Advanced / Metastatic

Open to Accrual

Low Accruing

Pending Activation


1L

2L

**UCI 23-148:** CJRB-01 (oral) + Pembrolizumab

Mechanism: Live biotherapeutic product containing a novel strain belonging in the species *Leuconostoc mesenteroides* (*L. mesenteroides* + Pembrolizumab)

Coord: TBD  
Accrual: 0/6

 Open to Accrual


 Low Accruing

 Pending Activation

**UCI 22-86:** Gut Microbiome Study

Mechanism: Fecal Collection  
Coord: Stefanie Fernandez  
Accrual: 0/82



 Open to Accrual

 Low Accruing

 Pending Activation

UCI 21-233: Mecbotamab  
vedotin (BA3011) &  
Nivolumab

Mechanism: Immunotherapy  
Coord: Jenny Choe  
Accrual: 1/10